Physician profile
Rajesh Kumar
NPI 1134272933
$3,356.32
in general payments reported to CMS, 2019-2025
25 companies · $614 in 2025
The $614 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $15.00 · 2021: $158 · 2022: $497 · 2023: $308 · 2024: $1,413 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503 · Travel and Lodging: $779 · Education: $53.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.17 |
| Travel and Lodging | $779.04 |
| Education | $53.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $831.59 | 2019-2025 | Farxiga, Lokelma |
| Abbott Laboratories | $779.04 | 2024 | Esprit |
| Travere Therapeutics, INC. | $282.18 | 2021-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $271.99 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $187.07 | 2021-2024 | |
| Amgen INC. | $113.90 | 2019-2025 | Tavneos, Krystexxa |
| Ardelyx, INC. | $101.32 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $90.71 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $70.76 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $69.55 | 2019-2025 | Veltassa |
| Novo Nordisk INC | $67.73 | 2024-2025 | Ozempic, Wegovy, Rivfloza |
| Opko Pharmaceuticals, LLC | $62.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $62.34 | 2023-2024 | |
| Horizon Therapeutics Plc | $58.20 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $55.96 | 2021-2024 | Lupkynis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $42.05 | 2021-2022 | |
| Lilly USA, LLC | $41.27 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.40 | 2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $29.54 | 2019 | |
| Pharmacosmos Therapeutics INC. | $27.99 | 2025 | Monoferric |
| Nxstage Medical, INC. | $26.80 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.09 | 2022 | |
| Fresenius USA Marketing, INC. | $13.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.53 | 2019 | |
| Cycle Pharmaceuticals INC | $5.55 | 2024 | Tiopronin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.